JNJ Fair Value — Johnson & Johnson

Drug Manufacturer · Institutional-depth multi-model valuation on Equity Rank

Current Price
$260.13
Consensus Fair Value
$184.95
Margin of Safety
-28.9%

When does JNJ report earnings?

Johnson & Johnson (JNJ) is next scheduled to report earnings on Oct 13, 2026. The consensus analyst EPS estimate for the upcoming quarter is $3.05.

Heading into this report, the model's fair value estimate sits 28.9% below the current price (model fair value differential below current price). Descriptive context only — not a forecast of the earnings result.

Earnings dates and estimates are sourced from third-party data and may change or lag. Informational only.

How JNJ's valuation models agree

Equity Rank computed model fair value for JNJ from 9 independent valuation methods with sufficient data. 2 place fair value above the current price of $260.13, and 7 place it below. The model-blended estimate lands at $184.95 — a model fair value differential of 28.9% below the current price under these model assumptions. The larger group places fair value below the current price.

Models: FV above price
2
Models: FV below price
7
Models compared
9

Each method (DCF, Graham Number, EPV, Three-Stage DCF, DDM, Residual Income, Justified Price-to-Book, and more) is weighted by historical sector accuracy. Model-derived and informational only — not investment advice.

JNJ fundamental profile

Equity Rank's fundamental strength composite scores JNJ at 72.4/100 (B+, Strong), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at +4.7% per year and gross margin has moved +3.5 pp. Its SAVE composite score has moved +2.7 over the past 30 days.

A composite quality metric for research context — not a rating, recommendation, or directional signal.

About JNJ

Johnson & Johnson (JNJ) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.

Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.

Related Drug Manufacturer Research

UNH · PFE · ABBV · MRK · LLY

Side-by-side valuation: JNJ vs PFE · JNJ vs ABBV

All Healthcare stocks with model fair values · Undervalued Healthcare stocks

Research Tools

Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator

Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks